Tourmaline Bio (NASDAQ:TRML – Get Free Report) and CERo Therapeutics (NASDAQ:CERO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.
Volatility and Risk
Tourmaline Bio has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.44, suggesting that its stock price is 144% less volatile than the S&P 500.
Profitability
This table compares Tourmaline Bio and CERo Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Tourmaline Bio | N/A | -19.56% | -18.91% |
CERo Therapeutics | N/A | N/A | -23.86% |
Institutional & Insider Ownership
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Tourmaline Bio and CERo Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tourmaline Bio | 0 | 0 | 6 | 0 | 3.00 |
CERo Therapeutics | 0 | 0 | 0 | 0 | N/A |
Tourmaline Bio currently has a consensus price target of $61.80, suggesting a potential upside of 304.72%. Given Tourmaline Bio’s higher probable upside, equities research analysts plainly believe Tourmaline Bio is more favorable than CERo Therapeutics.
Valuation & Earnings
This table compares Tourmaline Bio and CERo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tourmaline Bio | N/A | N/A | -$42.12 million | ($6.50) | -2.35 |
CERo Therapeutics | N/A | N/A | -$2.54 million | N/A | N/A |
Summary
Tourmaline Bio beats CERo Therapeutics on 5 of the 8 factors compared between the two stocks.
About Tourmaline Bio
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.